Nordic Nanovector to amend PARADIGME trial protocol to expand eligible patient population
Oslo, Norway, 30 June 2020 Nordic Nanovector ASA (OSE: NANO) announces that it will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool of eligible patients with the aim of increasing the present rate of enrolment. This decision has been made based on the company’s reviewed discussions with the US Food and Drug Administration (FDA). PARADIGME is the company’s ongoing pivotal, global, randomised Phase 2b trial investigating Betalutin® ([177]Lu-lilotomab satetraxetan) as a single administration in 3[rd]-line relapsed/refractory